Journal
NEUROBIOLOGY OF DISEASE
Volume 50, Issue -, Pages 21-29Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2012.09.003
Keywords
Alzheimer's disease; APP/PS1; TUDCA; Learning and memory; Morris water maze
Categories
Funding
- 7FP grant MEMOSAD
- Federal Science Fund FWO-Vlaanderen [G.0327.08]
- Fundacao para a Ciencia e a Tecnologia (FCT) [PTDC/SAU-NMC/117877/2010]
Ask authors/readers for more resources
Alzheimer's disease (AD) is a neurodegenerative disease hallmarked by extracellular A beta(1-42) containing plaques, and intracellular neurofibrillary tangles (NFT) containing hyperphosphoiylated tau protein. Progressively, memory deficits and cognitive disabilities start to occur as these hallmarks affect hippocampus and frontal cortex, regions highly involved in memory. Connective tissue growth factor (CTGF) expression, which is high in the vicinity of A beta plaques and NFTs, was found to influence gamma-secretase activity, the molecular crux in A beta(1-42) production. Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid that downregulates CTGF expression in hepatocytes and has been shown to possess therapeutic efficacy in neurodegenerative models. To investigate the possible in vivo therapeutic effects of TUDCA, we provided 0.4% TUDCA-supplemented food to APP/PS1 mice, a well-established AD mouse model. Six months of TUDCA supplementation prevented the spatial, recognition and contextual memory defects observed in APP/PS1 mice at 8 months of age. Furthermore, TUDCA-supplemented APP/PS1 mice displayed reduced hippocampal and prefrontal amyloid deposition. These effects of TUDCA supplementation suggest a novel mechanistic route for Alzheimer therapeutics. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available